A significant breakthrough in genetic research has identified a specific variant in a gene responsible for iron regulation that appears to significantly increase the risk of dementia in men. The study, which analyzed data from a massive cohort of healthy older individuals, found that men who carry two copies of a common genetic variant are twice as likely to develop dementia during their lifetime compared to women with the same genetic profile. These findings, published in the prestigious medical journal Neurology, offer new insights into the complex intersection of genetics, gender, and neurodegenerative disease, potentially opening doors for more personalized approaches to prevention and treatment.
The research focused on the haemochromatosis (HFE) gene, a critical component of the body’s internal machinery for regulating iron levels. While the HFE gene is well-known in clinical circles for its role in iron overload disorders, its specific relationship with cognitive decline and dementia has remained a subject of intense investigation. By utilizing data from the landmark ASPirin in Reducing Events in the Elderly (ASPREE) trial, researchers were able to look closely at how variations in this gene influence long-term brain health in a large, diverse population of aging adults.
According to the study’s findings, a specific variant of the HFE gene known as H63D is remarkably common in the general population. Professor John Olynyk, a co-author of the study from the Curtin Medical School, noted that the prevalence of this variant is higher than many might expect. Approximately one in three individuals carries a single copy of the H63D variant. In most cases, carrying just one copy does not appear to have a measurable impact on a person’s overall health or their likelihood of developing dementia. However, the risk profile changes dramatically for those who inherit two copies of the variant—one from each parent.
For the one in 36 people who carry two copies of the H63D variant, the research revealed a stark gender disparity. While women carrying two copies did not show a significantly increased risk of cognitive decline, men with the same genetic makeup faced more than double the risk of developing dementia. This discovery underscores the importance of sex-specific research in understanding neurodegenerative conditions, as the same genetic marker can manifest in vastly different ways depending on the biological context of the individual.
The biological mechanisms behind this increased risk remain a point of active inquiry. Professor Olynyk explained that while the genetic variant itself is a fixed part of an individual’s DNA and cannot be altered, the physiological pathways it influences could be targets for future medical intervention. The HFE gene is primarily responsible for managing how the body absorbs and stores iron, but the researchers found a surprising twist in the data. Despite the gene’s primary function, the study found no direct correlation between the levels of iron in the blood and the increased risk of dementia in the affected men.
This lack of a direct link to blood-iron levels suggests that the damage to the brain may be caused by other, more complex mechanisms. Professor Olynyk pointed toward the possibility of increased brain injury resulting from systemic inflammation and cellular damage within the body. If the H63D variant predisposes the brain to inflammatory responses or makes neural cells more vulnerable to oxidative stress, these pathways could potentially be treated or managed if scientists can gain a deeper understanding of the underlying processes.
The findings have significant implications for public health and clinical practice, particularly regarding genetic testing. In many Western countries, including Australia, the HFE gene is already routinely tested when doctors suspect a patient may have haemochromatosis—a condition where the body absorbs excessive amounts of iron, leading to organ damage over time. Given the newly discovered link to dementia risk, Professor Olynyk suggested that there may be a case for offering this genetic testing more broadly to men, even in the absence of traditional iron-disorder symptoms.
The ability to identify high-risk individuals through routine testing could be a game-changer for dementia prevention. Professor Paul Lacaze, a co-author from Monash University, emphasized that understanding these genetic nuances is essential for improving outcomes in a country where dementia is a leading cause of disability and death. Currently, more than 400,000 Australians are living with dementia, and men account for approximately one-third of that population. By pinpointing why men with the double H63D variant are more susceptible to the disease, researchers can move toward "precision medicine"—tailoring prevention strategies and treatments to a person’s specific genetic risks.
The strength of these findings is bolstered by the scale and rigor of the ASPREE trial, which provided the foundational data for the study. ASPREE was a massive, double-blind, randomized, placebo-controlled trial involving 19,114 healthy older people across Australia and the United States. While the trial was originally designed to evaluate whether a daily low dose of aspirin could prolong healthy life by preventing heart disease, stroke, or cancer, it inadvertently created what researchers describe as a "treasure trove" of data regarding the aging process.
Because the ASPREE participants were closely monitored over several years, the data set includes detailed information on genetics, lifestyle, and cognitive function. This wealth of information has allowed researchers to investigate a wide array of health issues beyond the original scope of the aspirin study. In this instance, the ASPREE data allowed the research team to track the cognitive health of thousands of individuals and correlate those outcomes with their HFE gene status, providing a level of statistical power that would be difficult to achieve in a smaller study.
The research also highlights the power of large-scale academic and clinical collaboration. The study was the result of a coordinated effort between several of Australia’s leading research institutions, including Curtin University, Monash University, and The University of Melbourne. Clinical support and data were also contributed by The Royal Children’s Hospital, the Murdoch Children’s Research Institute, and Fiona Stanley Hospital. According to Professor Lacaze, this collaborative model is essential for tackling progressive and complex diseases like dementia, which require expertise across genetics, neurology, and epidemiology.
As the global population ages, the burden of dementia is expected to grow, making the search for preventable risk factors more urgent than ever. The identification of the H63D variant as a male-specific risk factor provides a new lead for scientists trying to understand the "why" behind the disease. It also serves as a reminder that the drivers of dementia are not the same for everyone; gender, genetics, and environmental factors interact in ways that science is only beginning to untangle.
For now, the focus of the research team remains on the "why." Future studies will likely delve deeper into the inflammatory pathways mentioned by Professor Olynyk, seeking to determine exactly how the double H63D variant triggers the damage that leads to cognitive decline. If these pathways can be identified and interrupted, it may be possible to develop interventions that mitigate the risk for men carrying this variant, effectively neutralizing the genetic disadvantage they were born with.
Ultimately, this study contributes to a growing body of evidence that dementia is not an inevitable part of aging, but rather the result of specific biological processes that may, in time, be manageable. By leveraging the data from trials like ASPREE and the collaborative power of major research universities, the medical community is moving closer to a future where a person’s genetic code does not dictate their cognitive destiny. The discovery of the HFE gene’s role in male dementia is a vital step in that journey, offering a clearer picture of the risks faced by millions of men worldwide and providing a roadmap for the next generation of neurological research.
